New MRP Rules Cut Anti‑Cancer Medicine Costs, Over 600 Brands Reduce Prices by 50%+
Delhi, 9 Nov – A sweeping revision of maximum retail price (MRP) guidelines for anti‑cancer medicines has been implemented, covering 1,364 distinct formulations. The Department of Pharmaceuticals reported that 85 companies supplied revised MRPs for 121 drugs, affecting a total of 1,364 products.
Under the authority of the National Pharmaceutical Pricing Authority, trade‑margin limits were introduced for 137 cancer drugs, based on expert input from the Directorate General of Health Services. More than 600 brands—679 to be exact—have slashed their prices by at least half, and the steepest cut reaches 96.45 per cent.
The Ministry projects an aggregate saving of about ₹3,540.38 crore for patients over the coming financial year. The updated MRPs are enforceable from 9 November, and shoppers can confirm the new rates on product packaging or via the “Pharma Sahi Daam” app and the NPPA portal. Any pharmacy or hospital that attempts to charge above the revised price will be in violation of the new rules.